Timothy Devos

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano et al. · Journal of Clinical Oncology · 2017 · 345 citations · Full text

Hematological Malignancy, Immunohematology, Momelotinib 200 +13

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Francesco Passamonti, Toni Giorgino, Barbara Mora et al. · Leukemia · 2017 · 323 citations · Full text

Hematological Malignancy, Thrombosis, Translational Medicine +9

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Francesco Passamonti, Martin Grießhammer, Francesca Palandri et al. · The Lancet Oncology · 2016 · 245 citations

Polycythaemia Vera, Medicine, Pharmacology +2

KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia

Roel Willemze, Celso Arrais‐Rodrigues, Myriam Labopin et al. · Leukemia · 2009 · 243 citations · Full text

Transplantation, Marrow Transplantation, Medicine +11

G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells

Ariane Luyckx, Elio Schouppe, Omer Rutgeerts et al. · Clinical Immunology · 2012 · 90 citations

Cell Therapy, Medicine, Stem Cell Mobilization +12